Suppr超能文献

可乐定与卡托普利治疗高血压急症患者的疗效比较:一项随机临床试验。

Comparing outcomes of clonidine and captopril in patients with hypertensive urgency: A randomized clinical trial.

作者信息

Mirdamadi Ahmad, Abrishamkar Rana, Kargaran Afrooz

机构信息

Associate Professor, Department of Cardiology, Najafabad Branch, Islamic Azad University, Isfahan, Iran.

Medical Practitioner, Najafabad Branch, Islamic Azad University, Isfahan, Iran.

出版信息

ARYA Atheroscler. 2022 Jan;18(1):1-6. doi: 10.48305/arya.v18i1.2146.

Abstract

BACKGROUND

Hypertension (HTN) is the second leading risk factor for death and disability. One fourth of healthcare in Eastern Europe and Central Asia is being spent on blood pressure (BP)-related diseases. An important situation in patients with high BP is hypertensive crisis (BP > 180/120 mmHg), which is divided to hypertensive emergency and urgency. Therefore, here, we decided to compare the effect of captopril and clonidine in patients with hypertensive urgencies, and their side effects.

METHODS

This was a parallel-group randomized clinical trial. Patients, who referred to emergency ward with any symptoms of hypertensive crisis, underwent a careful history taking and clinical examination. Individuals with systolic BP (SBP) ≥ 180 mmHg or diastolic BP (DBP) ≥ 110 mmHg with no evidence of end organ damage were randomly assigned into two interventions, clonidine and captopril. 25% decrease in BP was considered as ideal relief.

RESULTS

Regarding the duration of response to treatment drugs, patients who received clonidine relieved significantly faster than those who received captopril (P = 0.016). Moreover, the frequencies of side effects such as headache, dizziness/vertigo, dry mouth, and drowsiness in the clonidine group were significantly lower than captopril group (P < 0.05).

CONCLUSION

Patients in clonidine group relieved sooner and experienced fewer side effects. Therefore, this study suggests clonidine as a more effective therapeutic for hypertensive urgency compared with captopril.

摘要

背景

高血压(HTN)是导致死亡和残疾的第二大风险因素。东欧和中亚地区四分之一的医疗保健支出用于治疗与血压(BP)相关的疾病。高血压患者的一种重要情况是高血压危象(血压>180/120 mmHg),可分为高血压急症和亚急症。因此,我们决定比较卡托普利和可乐定对高血压亚急症患者的疗效及其副作用。

方法

这是一项平行组随机临床试验。因任何高血压危象症状转诊至急诊病房的患者,均接受了详细的病史采集和临床检查。收缩压(SBP)≥180 mmHg或舒张压(DBP)≥110 mmHg且无终末器官损害证据的患者被随机分为两组进行干预,即可乐定组和卡托普利组。血压下降25%被视为理想的缓解效果。

结果

在治疗药物的反应持续时间方面,接受可乐定治疗的患者缓解速度明显快于接受卡托普利治疗的患者(P = 0.016)。此外,可乐定组头痛、头晕/眩晕、口干和嗜睡等副作用的发生率明显低于卡托普利组(P < 0.05)。

结论

可乐定组患者缓解更快,副作用更少。因此,本研究表明,与卡托普利相比,可乐定是治疗高血压亚急症更有效的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fe/9931607/fbe25fdd81eb/ARYA-18-2-2146f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验